CollPlant Biotechnologies , or 'CollPlant', a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue ...

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...

The mechanics of a PM deal are complex. Contracts are increasingly nuanced and bespoke, including caveats and clawbacks.

"The merger with Verde is an exciting opportunity for long-term value creation,” said Nxu Founder, Chairman and CEO Mark Hanchett. "Verde's PolyEarthylene resins are generating interest across the ...

TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERTTM platform to support the development and commercialization of azer-cel, ...

Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of technology and data, and Reddit, Inc., a community of communities, today announced an agreement for Intercontinental Exchange ...

We take a closer look at how European policymakers could react. Spoiler alert: it's complicated. The Trump hurricane ...

Lightbridge and INL teams at Idaho National Laboratory RESTON, Va., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Lightbridge Corporation ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended ant ...

Strong execution drives record fourth quarter net sales, significant margin expansion, and all-time record free cash flow generation; 2025 outlook an ...

Since announcing its intent to pursue FedRAMP authorization, the Cellebrite Government Cloud was reviewed by a Third-Party Assessment Organization (3PAO), and the FedRAMP Program Management Office ...